Prospective Clinical Evaluation of BD NRFit™ Devices and Accessories.

Becton, Dickinson and Company161 enrolled

Overview

Multi-center, prospective, open label, single arm post-market study to assess the real-world safety and efficacy of BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes used in an on-market fashion.

This is a multi-center, prospective, open label, single arm post-market study that will enroll approximately 180 participants in order to have a minimum of 150 treated participants who will receive a spinal anesthesia procedure as part of their routine medical care. Participants will be followed from the time of enrollment for up to 10 days (± 3 days) post spinal anesthesia procedure for evidence of adverse events including Post Dural Puncture Headache (PDPH). This can be done via phone if the participant is discharged from the hospital. The site staff must take advantage of the time window of ± 3 days only when the 10-day post-procedure occurs during the weekends or holidays. Any adverse event or complication must be diagnosed and confirmed by a study physician. A minimum of 50 participants for each of the two needle tip types (Quincke and Whitacre tip) will be enrolled in the study.

Study Type

OBSERVATIONAL

Enrollment

161

Conditions

Anesthesia Analgesia

Interventions

BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ SyringesDEVICE

Insertion of a BD NRFit™ spinal needle and optional BD NRFit™ Spinal Introducer Needle using a BD NRFit™ Syringe to perform the neuraxial procedure.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Any patient, regardless of age or gender, for which the investigator has decided that a neuraxial procedure must be performed utilizing BD NRFit™ Spinal Needles, NRFit™ Spinal Introducer Needles, and NRFit™ Syringes as part of their routine medical care. 2. Expected to be available for observation through the study period (10 days, ± 3 days, post procedure\*). 3. Able and willing to provide signed and dated informed consent or legal authorized representative (LAR) authorized to give consent on behalf of the participant (Note: Consent of guardian or parent may be required for participants under the age of 18 years; participant assent may be required as well). Exclusion Criteria: 1. Coagulopathy or bleeding disorder, where it is in the opinion of the investigator makes regional anesthetic of increased risk. 2. Subjects with a history of neurological impairment of the trunk or lower extremities. 3. Infection at the site of needle insertion. 4. Previous spine surgery at the level involved in the study procedure.

Locations (5)

Barmherzige Bruder Krankenhaus Salzburg

Salzburg, Austria

Medizinische Universität Wien

Vienna, Austria

Charité Campus Benjamin Franklin

Berlin, Germany

Universitätsklinikum Leipzig

Leipzig, Germany

Outcomes

Primary Outcomes

Primary Performance: Rate of Participants With Successful BD Spinal NRFit™ Needle Placement in the Subarachnoid Location

Percentage of participants with successful placement of the BD Spinal NRFit™ needle in the subarachnoid location defined as the spontaneous appearance of cerebrospinal fluid (CSF) emerging from the spinal needle hub.

Time frame: During insertion procedure

Primary Performance: Rate of of Participants With Successful Needle Placement in the Subarachnoid Location When a BD Spinal NRFit™ Introducer is Used

Time frame: During insertion procedure

Primary Performance: Rate of Participants With Successful Aspiration Through BD NRFit™ Syringes

Percentage of participants with successful aspiration of anesthetic through a BD NRFit™ Syringe.

Time frame: During insertion procedure

Primary Performance: Rate of Participants With BD NRFit™ Syringes That do Not Leak at the Connection Point During Medication Administration

Percentage of participants with BD NRFit™ Syringes that do not leak at the connection point during medication administration.

Time frame: During insertion procedure

Primary Safety: Rate of Participants With a Diagnosis of Post Dural Puncture Headache (PDPH)

Percentage of participants with a diagnosis of PDPH (defined as headache that worsens when standing/upright position and relieves when laying supine) for a period of up to 10 (± 3 days) days following the procedure.

Time frame: From insertion up to 10 (± 3 days) post procedure

Primary Safety: Percentage of Participants With Any Study Device and Procedure Adverse Events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.